TAVR at a Crossroads: What CMS’s 2026 Coverage Overhaul Really Means

When Medicare first covered transcatheter aortic valve replacement (TAVR) in 2012, it did so cautiously — paying only when patients were enrolled in a national registry and treated at centers that met strict volume and heart-team requirements. A 2019 update eased some of those entry barriers but kept the core bargain intact: cover the procedure but keep collecting the evidence. In 2026, for the first time, CMS is proposing to take that bargain apart.

The 2026 Proposal in Brief

CMS’s proposed national coverage determination — open for public comment through July 15, 2026, with a final decision expected around September 13 — makes three significant moves. First, it would extend coverage to patients with asymptomatic severe aortic stenosis, but still under coverage with evidence development (CED). Second, and most consequentially, it would end CED for symptomatic patients, lifting the evidence-collection mandate that has governed TAVR since 2012. Third, it would loosen — though not eliminate — the operator and volume requirements, swapping institution-level open-heart-surgery prerequisites for an operator-level threshold of roughly 20 transcatheter valve procedures a year, at least 15 of them TAVI. One change CMS had floated — dropping cardiac surgeons from the heart team — did not make the cut.

The Economics of Expansion

The financial logic runs in one direction — expansion. Roughly a third of severe aortic stenosis is asymptomatic, so covering that population materially enlarges the eligible pool, a clear win for device makers Edwards and Medtronic. (Edwards, which sponsored the pivotal EARLY TAVR trial, requested this reconsideration.) Ending CED also strips out the administrative cost of mandatory registry enrollment and follow-up, lowering the operational burden of running a program. And because the proposal opens the door to younger, lower-risk patients, it sets up a lifetime-sequencing dynamic: a 60-year-old who receives TAVR first is statistically likely to need a second valve procedure later — more procedures per patient over time. More eligible patients, more sites, more operators, less paperwork: every vector points toward higher volume.

The Future of the Heart Team

The multidisciplinary heart team survived. After pushback from the cardiology and surgical communities, CMS explicitly preserved both its concept and its composition. But the loosened operator language worries the Society of Thoracic Surgeons, which reads it as a possible backdoor to single-operator TAVR performed without a surgeon. The likely result is a two-tier landscape: high-volume comprehensive valve centers will keep a genuine surgical partner at the table, while lower-volume sites drift toward interventional-cardiologist-led programs. The rule keeps the heart team on paper; whether it stays meaningful in practice will vary center by center.

Strip away the mandate and the surgeon’s incentive to stay engaged grows thin everywhere but the largest programs. The cases where a surgeon genuinely changes management — marginal candidates, anatomy better served by open repair, patients who are not TAVR candidates at all — get referred to surgery on their merits anyway, whether or not a surgeon sat in on the original evaluation. For the routine majority, surgical sign-off adds a scheduling step and a second opinion the interventional cardiologist rarely needs and, practically speaking, would often just as soon do without. Outside the high-volume comprehensive centers — where surgeons and interventionalists already share a single valve practice — the heart team risks becoming a formality that quietly erodes once it is no longer required.

Stakeholders at a Glance

• Device Industry (Edwards, Medtronic): Wins — a bigger addressable market and a “successful graduation” from CED.
• Interventional Cardiologists: Gain ground — more autonomy and reach as the gates loosen.
• Cardiac Surgeons: Lose relative standing — though heart-team membership is preserved for now.
• Medical Societies (STS, ACC, SCAI, AATS, HFSA): United that CED should continue. STS is the most critical; ACC is still reviewing; SCAI is broadly aligned with the added flexibility.
• Patients: Better access and more sites — but the loss of the registry surveillance that has tracked their outcomes.

What it Means for Quality

Here is the central tension. The STS/ACC TVT Registry has been TAVR’s quality backbone since 2012, capturing the real-world outcomes that volume thresholds were only ever meant to approximate. Ending CED for symptomatic patients removes that surveillance stream at the very moment coverage expands into newer, less-studied territory. Procedural safety in lower-risk patients is largely a solved problem; the harder questions now are about patient selection and long-term outcomes — exactly what a registry is built to answer. CMS is betting that TAVR has matured past the need for mandated evidence development. The societies counter that you don’t take the instruments off the patient just as you widen the indication.

What to Watch: by September 13, whether CMS holds the line on ending symptomatic-patient CED over near-unanimous society objection — and how tightly it draws the operator definition to keep TAVR a team sport.

Sources

• CMS, Proposed Decision Memo for TAVR (CAG-00430R2), June 15, 2026; National Coverage Determination §20.32.
• Joint society comment letter — AATS, ACC, HFSA, SCAI, and STS, January 14, 2026 (“continuation of the CED paradigm is essential”).
• Cardiovascular Business — reporting on the three proposed changes and society reactions, including STS President Vinay Badhwar and SCAI President J. Dawn Abbott statements.
• STS, ACC, and SCAI — official society statements on the June 2026 proposal.
• TCTMD — operator-definition details, EARLY TAVR (TCT 2024; NEJM), and heart-team evaluation logistics. Healthcare Dive — end of CED for symptomatic patients and loosened site/operator gates.

By Steven D. Harrington, MD, MBA, FACS, ABTS, FACC, FACCP